Published in Pharm Res on January 01, 1989
Targeted prodrug design to optimize drug delivery. AAPS PharmSci (2000) 1.36
Molecular interactions between dipeptides, drugs and the human intestinal H+ -oligopeptide cotransporter hPEPT1. J Physiol (2006) 0.96
Function and immunolocalization of overexpressed human intestinal H+/peptide cotransporter in adenovirus-transduced Caco-2 cells. AAPS PharmSci (1999) 0.84
The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme. Molecules (2012) 0.78
Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption. J Biomed Sci (2010) 0.75
Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors. Proc Natl Acad Sci U S A (1983) 3.17
The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res (1997) 2.28
Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm (2000) 2.14
Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res (1998) 2.08
Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res (1996) 2.05
5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res (1998) 1.66
Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test. Clin Pharmacol Ther (1997) 1.64
Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J Pharmacol Exp Ther (1984) 1.45
Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci (2000) 1.45
Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci (2004) 1.41
Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints. Biophys J (1998) 1.38
Targeted prodrug design to optimize drug delivery. AAPS PharmSci (2000) 1.36
A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm (1999) 1.35
Modulation of mu-mediated antinociception in the mouse involves opioid delta-2 receptors. J Pharmacol Exp Ther (1992) 1.32
Indoor environmental quality in six commercial office buildings in the midwest United States. Appl Occup Environ Hyg (2001) 1.30
Membrane topology of the human dipeptide transporter, hPEPT1, determined by epitope insertions. Biochemistry (1998) 1.23
Human postprandial gastric emptying of 1-3-millimeter spheres. Gastroenterology (1988) 1.23
Absorption potential: estimating the fraction absorbed for orally administered compounds. J Pharm Sci (1985) 1.21
Systemic analgesic activity and delta-opioid selectivity in [2,6-dimethyl-Tyr1,D-Pen2,D-Pen5]enkephalin. J Med Chem (1992) 1.20
The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J Pharmacokinet Biopharm (1987) 1.20
Moisture sorption kinetics for water-soluble substances. I: Theoretical considerations of heat transport control. J Pharm Sci (1983) 1.19
Differential antagonism of opioid delta antinociception by [D-Ala2,Leu5,Cys6]enkephalin and naltrindole 5'-isothiocyanate: evidence for delta receptor subtypes. J Pharmacol Exp Ther (1991) 1.18
Direct dependence studies in rats with agents selective for different types of opioid receptor. J Pharmacol Exp Ther (1988) 1.17
Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J Pharmacol Exp Ther (1993) 1.17
Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv Drug Deliv Rev (1996) 1.17
Role of mu and delta receptors in the supraspinal and spinal analgesic effects of [D-Pen2, D-Pen5]enkephalin in the mouse. J Pharmacol Exp Ther (1987) 1.15
Prediction of physical aging in controlled-release coatings: the application of the relaxation coupling model to glassy cellulose acetate. Pharm Res (1991) 1.14
Influence of physical aging on mechanical properties of polymer free films: the prediction of long-term aging effects on the water permeability and dissolution rate of polymer film-coated tablets. Pharm Res (1991) 1.13
Scaleup of immediate release oral solid dosage forms. Pharm Res (1993) 1.10
Key residues defining the mu-opioid receptor binding pocket: a site-directed mutagenesis study. J Neurochem (1997) 1.10
The transmembrane 7-alpha-bundle of rhodopsin: distance geometry calculations with hydrogen bonding constraints. Biophys J (1997) 1.10
Modulation of the potency and efficacy of mu-mediated antinociception by delta agonists in the mouse. J Pharmacol Exp Ther (1990) 1.09
Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm Res (2000) 1.09
Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys. J Pharmacol Exp Ther (1999) 1.08
Pharmacokinetics of trimethoprim and sulfamethoxazole in normal subjects and in patients with renal failure. J Infect Dis (1973) 1.08
Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res (1998) 1.07
Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol). J Pharm Sci (2006) 1.07
kappa-Opioid receptor binding populations in rhesus monkey brain: relationship to an assay of thermal antinociception. J Pharmacol Exp Ther (1998) 1.06
Lack of antinociceptive cross-tolerance between [D-Pen2, D-Pen5]enkephalin and [D-Ala2]deltorphin II in mice: evidence for delta receptor subtypes. J Pharmacol Exp Ther (1991) 1.06
Characterization of [3H][2-D-penicillamine, 5-D-penicillamine]-enkephalin binding to delta opiate receptors in the rat brain and neuroblastoma--glioma hybrid cell line (NG 108-15). Proc Natl Acad Sci U S A (1985) 1.05
HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. J Pharm Sci (1996) 1.05
Opioid delta-receptor involvement in supraspinal and spinal antinociception in mice. Brain Res (1987) 1.04
Novel approach to the analysis of in vitro-in vivo relationships. J Pharm Sci (1996) 1.03
Modulation of mu-mediated antinociception by delta agonists in the mouse: selective potentiation of morphine and normorphine by [D-Pen2,D-Pen5]enkephalin. Eur J Pharmacol (1989) 1.03
Protein denaturation during freezing and thawing in phosphate buffer systems: monomeric and tetrameric beta-galactosidase. Arch Biochem Biophys (2000) 1.02
Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm Res (1993) 1.02
Biology of membrane transport proteins. Pharm Res (1995) 1.02
Conformationally constrained cyclic enkephalin analogs with pronounced delta opioid receptor agonist selectivity. Life Sci (1983) 1.02
[D-Pen2, L-Cys5]enkephalinamide and[D-Pen2, D-Cys5] enkephalinamide, conformationally constrained cyclic enkephalinamide analogs with delta receptor specificity. Biochem Biophys Res Commun (1982) 1.00
Microbiologically influenced corrosion in petroleum product pipelines--a review. Indian J Exp Biol (2003) 1.00
Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy. Clin Pharmacol Ther (2011) 1.00
Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems. J Control Release (1999) 0.98
In vitro and in vivo assessment of adenovirus 41 as a vector for gene delivery to the intestine. Gene Ther (1998) 0.98
A peptide prodrug approach for improving bisphosphonate oral absorption. J Med Chem (2000) 0.98
Role of integrin expression in adenovirus-mediated gene delivery to the intestinal epithelium. Hum Gene Ther (1998) 0.98
Predicting fraction dose absorbed in humans using a macroscopic mass balance approach. Pharm Res (1991) 0.98
Characterization of bioresidues for biooil production through pyrolysis. Bioresour Technol (2013) 0.97
Supraspinal and spinal potency of selective opioid agonists in the mouse writhing test. J Pharmacol Exp Ther (1987) 0.97
Solubility of nonelectrolytes in polar solvents II: solubility of aliphatic alcohols in water. J Pharm Sci (1974) 0.97
Cerebral delta opioid receptors mediate analgesia but not the intestinal motility effects of intracerebroventricularly administered opioids. J Pharmacol Exp Ther (1984) 0.96
Hibiscus sabdariffa affects ammonium chloride-induced hyperammonemic rats. Evid Based Complement Alternat Med (2007) 0.96
Solubility of nonelectrolytes in polar solvents IV: nonpolar drugs in mixed solvents. J Pharm Sci (1976) 0.96
Structural requirements for delta opioid receptor binding. Mol Pharmacol (1987) 0.96
Time-dependent oral absorption models. J Pharmacokinet Pharmacodyn (2001) 0.95
Membrane permeability parameters for some amino acids and beta-lactam antibiotics: application of the boundary layer approach. J Theor Biol (1988) 0.95
Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant. J Pharm Sci (2000) 0.95
Human proton/oligopeptide transporter (POT) genes: identification of putative human genes using bioinformatics. AAPS PharmSci (2000) 0.95
Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm Res (1990) 0.94
Viscoelastic properties of polyacrylic acid gels in mixed solvents. Pharm Res (1992) 0.94
Evidence for mu opioid receptor mediation of enkephalin-induced electroencephalographic seizures. J Pharmacol Exp Ther (1987) 0.94
Cyclic penicillamine containing enkephalin analogs display profound delta receptor selectivities. Life Sci (1983) 0.93
Opioid delta receptor subtypes are associated with different potassium channels. Eur J Pharmacol (1991) 0.93
Characterization of the oral absorption of beta-lactam antibiotics. I. Cephalosporins: determination of intrinsic membrane absorption parameters in the rat intestine in situ. Pharm Res (1988) 0.93
Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter. J Pharmacol Exp Ther (2001) 0.93
Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects. Dig Dis Sci (1987) 0.93
Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery. Pharm Res (1992) 0.93
Quantification of helix-helix binding affinities in micelles and lipid bilayers. Protein Sci (2004) 0.93
Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. Eur J Pharm Biopharm (1998) 0.93
Analysis of models for determining intestinal wall permeabilities. J Pharm Sci (1980) 0.92
Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. J Pharm Sci (1989) 0.92
Scaleup of oral extended-release dosage forms. Pharm Res (1993) 0.92
Characterization of the oral absorption of beta-lactam antibiotics. II. Competitive absorption and peptide carrier specificity. J Pharm Sci (1989) 0.92
Passive and carrier-mediated intestinal absorption components of captopril. J Pharm Sci (1988) 0.92
Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci (1986) 0.92
Calculation of the aqueous diffusion layer resistance for absorption in a tube: application to intestinal membrane permeability determination. Pharm Res (1991) 0.91
Fatal hemoptysis in acute bacterial endocarditis. Am Rev Respir Dis (1988) 0.91
Pharmacokinetics of probenecid following oral doses to human volunteers. J Pharm Sci (1982) 0.90
Design of high affinity cyclic pentapeptide ligands for kappa-opioid receptors. J Pept Res (2005) 0.90
Modulation of mu-mediated antinociception by delta agonists: characterization with antagonists. Eur J Pharmacol (1989) 0.90
CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci (1999) 0.90
Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharm Res (1997) 0.90
Overexpression of human intestinal oligopeptide transporter in mammalian cells via adenoviral transduction. Pharm Res (1998) 0.90
Infected primary intramuscular echinococcosis of thigh. Indian J Pediatr (2005) 0.90
Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine. J Pharmacol Exp Ther (1988) 0.90
Modulated drug release using iontophoresis through heterogeneous cation-exchange membranes. 2. Influence of cation-exchanger content on membrane resistance and characteristic times. J Pharm Sci (1994) 0.90
History of preventive and social medicine in India. J Postgrad Med (2002) 0.89
Beta cyclodextrins enhance adenoviral-mediated gene delivery to the intestine. Pharm Res (1998) 0.89
Structure-based design, synthesis, and pharmacologic evaluation of peptide RGS4 inhibitors. J Pept Res (2004) 0.89